Other languages Alzamend Neuro, Inc.

Equities

ALZN

US02262M4078

Market Closed - Nasdaq Other stock markets 16:30:00 2024-04-30 EDT			5-day change	1st Jan Change
0.711 ^USD	+0.14%		-2.01%	-20.11%

03-25	Alzamend Neuro, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended January 31, 2024	CI
01-31	Alzamend Neuro, Inc. announced that it expects to receive $6 million in funding from Ault Lending, LLC	CI

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Alzamend Neuro, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended January 31, 2024	03-25
Alzamend Neuro, Inc. Appoints Milton C. Ault, III as a Director and Vice Chairman	01-05
Alzamend Neuro, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended October 31, 2023	12-15
Alzamend Neuro, Inc. Receives FDA " Study May Proceed" Notification for A Phase IIA Clinical Trial of Al001, A Next-Generation Lithium Therapeutic Drug Candidate, in Post-Traumatic Stress Disorder Patients	12-11
Alzamend Neuro Receives FDA Approval to Proceed With Phase 2A Study of AL001 Depression Treatment Candidate	11-20
Alzamend Neuro Receives FDA " Study May Proceed" Notification for A Phase IIA Clinical Trial of Al001, A Next-Generation Lithium Therapeutic Drug Candidate, in Major Depressive Disorder Patients	11-20
Alzamend Neuro, Inc. Submits IND Application for A Phase IIa Clinical Trial in Post-Traumatic Stress Disorder Patients of Next-Generation Lithium Therapeutic Drug Candidate AL001	11-13
Wall Street Set to Open Higher Monday as Investors Parse Earnings, Await Fed Meeting	23-10-30
Alzamend Neuro Seeks FDA Nod to Start Trial in Major Depressive Disorder	23-10-23
Alzamend Neuro, Inc. Submits Investigational New Drug Application for A Phase IIA Clinical Trial in Major Depressive Disorder Patients of Its Next-Generation Lithium Therapeutic Drug Candidate AL001	23-10-23
Alzamend Neuro, Inc Receives FDA ?Study May Proceed? Notification for a Phase IIA Clinical Trial of AL001, a Next-Generation Lithium Therapeutic Drug Candidate, in Bipolar Disorder Patients	23-10-02
Alzamend Neuro Secures Extension to Regain Compliance With Nasdaq's Minimum Bid Price Rule	23-09-25
Alzamend Neuro, Inc. Reports Earnings Results for the First Quarter Ended July 31, 2023	23-09-13
Alzamend Neuro Files New Drug Application With FDA to Begin Bipolar Disorder Study of Investigational Therapy AL001	23-08-30
Alzamend Neuro, Inc. Reports Earnings Results for the Full Year Ended April 30, 2023	23-07-27
Alzamend N Neuro, Inc. Announces Positive Phase IIA Clinical Trial Results for AL001	23-06-22
Alzamend Neuro Launches Phase 1/2a Trial of Vaccine Candidate to Treat Dementia Linked to Alzheimer's	23-04-03
Alzamend Neuro, Inc Announces the Initiation of A Phase I/Iia Trial for Its Immunotherapy Vaccine to Treat Mild to Moderate Dementia of the Alzheimer’S Type	23-04-03
Alzamend Neuro, Inc. Announces Completion of Clinical Portion of Phase IIA Multiple Ascending Dose Clinical Trial for AL001 Treatment of Dementia Related to Alzheimer's	23-03-22
Alzamend Neuro, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended January 31, 2023	23-03-15

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Alzamend Neuro, Inc.

Equities

ALZN

US02262M4078

Other languages

Filters